ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anlotinib

Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.

Drug pageAnlotinib: every studyMany companies study it; this page follows only the 40 they lead. All 374 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 30, 201340 company-led studies, 7 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical311 open or runningphase 3since Dec 30, 2013Mar 29, 2013none ahead
Advenchen Laboratoriesits history only32 open or runningphase 3since Aug 28, 2015Sep 26, 2014Dec 2027phase 3 · NCT03016819
Advenchen Laboratories Nanjingits history only11 open or runningphase 1since Feb 11, 2026Feb 11, 2026Mar 31, 2027phase 1 · NCT07438886
Advenchen Pharmaceuticals, LLC.its history only11 open or runningphase 2since Aug 12, 2026Aug 12, 2026Sep 1, 2030phase 2 · NCT07811297
Akesoits history only10 open or runningphase 2since Nov 23, 2020Nov 23, 2020none ahead
Fosun Pharmaits history only11 open or runningphase 2since Apr 25, 2026Apr 25, 2026Jun 2029phase 2 · NCT07562581
Lyvgen Biopharmaits history only10 open or runningphase 2since Mar 2, 2022Mar 2, 2022none ahead
Shanghai Gopherwood Biotechits history only11 open or runningphase 2since Jan 12, 2023Jan 12, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sino Biopharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Mar 29, 2013.

  1. Jun 29, 2016Phase 1 study in Advanced CancerNCT02825563 · 22 enrolled · China
  2. Feb 16, 2017Phase 2 study in Small Cell Lung CarcinomaNCT03059797 · 120 enrolled · China
  3. Feb 27, 2018Phase 2 study in Gastroenteropancreatic Neuroendocrine Tumor G3NCT03457844 · 60 enrolled · China
  4. Apr 18, 2018Phase 2 study in Bone NeoplasmsNCT03527888 · 40 enrolled · China
  5. Jan 30, 2019Phase 2 study in Carcinoma, HepatocellularNCT03825705 · 60 enrolled · China
  6. Aug 26, 20192 phase 3 studiesNCT04073537, NCT04073550
  7. Sep 25, 2019Phase 2 study in Gastrointestinal Stromal TumorsNCT04106024 · 60 enrolled · China
  8. Dec 30, 2019Phase 2 study in Advanced MalignancyNCT04216082 · 93 enrolled · China
  9. Jan 16, 2020Phase 3 study in Extensive Small Cell Lung CancerNCT04234607 · 738 enrolled · China
  10. Mar 25, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04325763 · 315 enrolled · China
  11. Sep 30, 2020Phase 2 study in Advanced Endometrial CancerNCT04574284 · 170 enrolled · China
  12. Jun 17, 2024Phase 3 study in Small Cell Lung Cancer Limited StageNCT06469879 · 358 planned · China
  13. Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06507891 · 30 enrolled · China
  14. Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177

TargetBeta

“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440

Studies

All 31 Sino Biopharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06507891Carcinoma, Non-Small-Cell Lung · China2TerminatedAug 25, 202330
NCT06469879Small Cell Lung Cancer Limited Stage · China3Not yet recruitingSep 2026358
NCT04574284Advanced Endometrial Cancer · China2CompletedNov 9, 2023170
NCT04325763Carcinoma, Non-Small-Cell Lung · China3UNKNOWNDec 2022315
NCT04234607Extensive Small Cell Lung Cancer · China3UNKNOWNDec 2022738
NCT04216082Advanced Malignancy · China2CompletedAug 31, 201493
NCT04106024Gastrointestinal Stromal Tumors · China2UNKNOWNOct 30, 201960
NCT04073550Small Cell Lung Carcinoma · China3UNKNOWNJul 31, 2021184
NCT04073537Squamous Non-small Cell Lung Cancer · China3UNKNOWNJul 31, 2021386
NCT03825705Carcinoma, Hepatocellular · China2UNKNOWNJan 1, 202160
NCT03527888Bone Neoplasms · China2UNKNOWNDec 31, 201940
NCT03457844Gastroenteropancreatic Neuroendocrine Tumor G3 · China2UNKNOWNAug 30, 201960
NCT03059797Small Cell Lung Carcinoma · China2CompletedJun 30, 2018120
NCT02825563Advanced Cancer · China1CompletedAug 15, 201822
NCT02809534Carcinoma, Hepatocellular · China2UNKNOWNDec 201760
NCT02752516Neoplasms · China1UNKNOWNDec 201716
NCT02649361Esophageal Squamous Cell Carcinoma · China2CompletedJul 23, 2018164
NCT02622932Advanced Solid Tumors · China1CompletedDec 30, 20166
NCT02586350Carcinoma, Medullary · China3CompletedSep 30, 201891
NCT02586337Differentiated Thyroid Cancer · China3UNKNOWNDec 2019113
NCT02461407Stomach Neoplasms · China3UNKNOWNDec 2017378
NCT02449343Sarcoma · China3UNKNOWNApr 2017233
NCT02388919Carcinoma, Non-Small-Cell Lung · China3CompletedJan 5, 2017439
NCT02332499Colorectal Neoplasms · China3CompletedAug 18, 2016419
NCT02072044Carcinoma, Renal Cell · China2UNKNOWNDec 201760
NCT02072031Anlotinib · China2UNKNOWNDec 2016133
NCT02029209Carcinoma, Non-Small-Cell Lung · China3UNKNOWNMar 2017110
NCT01924195Carcinoma, Non-Small-Cell Lung · China2CompletedMar 2015117
NCT01878448Neoplasms · China2CompletedOct 2015166
NCT01874873Neoplasms · China2CompletedDec 201658
NCT01833923Advanced Cancer · China1CompletedOct 201535

How it is read

Names in the registry

  • “Anlotinib”, 27 entries
  • “AL3818”, 5 entries
  • “AK104+anlotinib”, 3 entries
  • “luvometinib + anlotinib”, 2 entries
  • “Anlotinib and 14C-labeled Anlotinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.